Fig. 1
From: Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab
( a ) Timeline of diagnosis, treatment and immune-related adverse events ( b ) Post-treatment PET scan from April 2017: Initial L inguinal mass, as well as cerebral metastasis have resolved. Unrelated persistent bilateral parotid FDG-avidity which remained stable over serial PET scans ( c ) Replacement of the lymph node tissue by diffuse infiltrate of large malignant cells with occasional intranuclear inclusions (black arrows) [400x]. ( d ) Metastatic melanoma diagnosis confirmed by strong nuclear positivity for SoX-10 on immunohistochemical staining [200x] and ( e ) diffuse S-100 positivity [200x]. Immunostaining of tumour infiltrating lymphocytes showing positivity for T-cell markers ( g ) CD4 [200x], and ( h ) CD8 [200x]